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Letter
Eradication of pulmonary methicillin-resistant
staphylococcus aureus (MRSA) in cystic fibrosis with
linezolid
Dear sirs, we have had recent success with complete
eradication of initial pulmonary methicillin-resistant
Staphylococcus aureus (MRSA) colonisation in an adult
cystic fibrosis (CF) patient with a single outpatient
course of oral linezolid, now followed for over 18
months without evidence of recurrence.
A 28-year-old male with mild CF lung disease (FEV1
82% predicted) colonised with both Pseudomonas aeru-
ginosa and Staphylococcus aureus, presented with an
exacerbation of lung disease associated with increased
sputum production and purulence and decline in FEV .1
MRSA was isolated for the first time on sputum culture,
with repeat sputum culture confirming this. Further
investigations revealed a highly mupirocin-resistant epi-
demic MRSA-16, with both MecA and MupA genes
present. The patient received 2 weeks of oral linezolid,
600 mg twice daily, in conjunction with 1 week of daily
chlorhexidene washes and cream applied to the nares,
with resolution of his symptoms of increased pulmonary
infection. Sputum culture performed 7 days after com-
pletion of the course failed to culture MRSA. The patient
has now been followed for over 18 months, with no
evidence of recurrence of MRSA on multiple serial spu-
tum cultures, although bronchoalveolar lavage has never
been performed. We believe that this represents the first
reported case of complete eradication of pulmonary
MRSA in a CF patient with the use of oral linezolid.
Ferrin et al. have recently reported treatment of MRSA
pulmonary infection with linezolid in a CF patient, and
although therapy was associated with improved clinical
status, MRSA was never eradicated w1x.
Our patient lived over an hour away by ferry, and
inpatient management for prescription and monitoring of
intravenous vancomycin was not possible for personal
reasons. Nebulised vancomycin in the management of
pulmonary MRSA infection in a single patient with CF
has previously been reported however may be associated
with bronchospasm w2x. Due to our patient’s geographic
situation we were reluctant to prescribe nebulised van-
comycin therapy as an outpatient. The use of linezolid
for MRSA eradication is associated with both substantial
cost (£89 per day, £1246 for 2 week course), and the
risk of development of resistance with its widespread
use, however, in this current case the savings on inpa-
tient management and the individual benefit to this
patient justified its use.
Although there is no convincing evidence that pul-
monary MRSA colonisation in CF adversely effects pul-
monary function or outcome, a recent retrospective
review of 10 CF children with MRSA colonisation sug-
gested poorer growth and more courses of intravenous
antibiotics following colonisation than in non-colonised
controls w3x. Eradication at first isolation simplifies
future management of pulmonary disease (including
antibiotic regimes, reducing likelihood of adverse drug
reactions, issues relating to patient isolation, etc.) and
MRSA colonisation may be a contraindication to future
lung transplantation. Additionally, and perhaps most
importantly, successful eradication is likely to reduce the
psychological impact that knowledge of MRSA coloni-
sation may have on the individual with CF, as well as
attenuating stigmatisation within the CF clinic. Oral line-
zolid may be an effective agent for the eradication of
MRSA colonisation in selected patients with CF.
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